Neu­rode­gen­er­a­tion up­start De­nali out­lines $100M IPO for its grow­ing clin­i­cal work

Can a team of neu­rode­gen­er­a­tion spe­cial­ists and at least one ear­ly-stage drug as­set out of Roche’s world-fa­mous Genen­tech group suc­ceed where so many have failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER